Mesoblast Sees Chance For Faster Phase III Heart Failure Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The Australian stem cell company said a Phase III trial being run by partner Teva and testing MPC-150-IM in chronic heart failure could finish earlier than expected because of an interim superiority analysis.
You may also be interested in...
Regenerative Medicine Finally Feels The Love
Investment in regenerative medicine has boomed over the past couple years, according to data presented at the Alliance for Regenerative Medicine's third annual Regen Med Investor Day, and all signs point to an even bigger year in 2015.
Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology
Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.